Dalerba et al. showed that lack of CDX-2 expression is correlated with high-risk stage II colon cancer that may probably benefit from adjuvant chemotherapy23, and Aasebo et al. found that CDX-2 immunochemistry loss is an independent negative prognostic factor for survival in mCRC24. This evidence concerns the gene CDX2 and colonic neoplasm.